5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes

5. 11. 2009 - 7. 11. 2009, New York Marriott at The Brooklyn Bridge, New York, USA

Aktivní účast

  • Podávání abstrakt do 18. srpna 2009

Registrace

Thursday November 5, 2009
8:00 am Welcome and Introduction Richard T. Silver, MD, FACP
Session I: Myelodysplastic Syndromes Chairs: John M. Bennett, MD and Alan F. List, MD
8:30 am Classification, morphology, and pathogenesis of myelodysplastic diseases John M. Bennett, MD
9:00 am The interface of aplastic anemia and MDS; treatment measures Neal S. Young, MD
9:30 am Current treatment, including hypomethylating agents Alan F. List, MD
10:00 am New drugs in MDS – Treatment of iron overload Gail J. Roboz, MD
10:30 am Break
11:00 am Which transplant and when for patients with MDS? Speaker invited
11:30 am Keynote Address: Normal and neoplastic stem cells Speaker invited
12:15 pm Discussion / Questions
12:30 pm Lunch
Session II: Myelofibrosis Chair: Ayalew Tefferi, MD
1:30 pm Allogeneic transplantation in primary myelofibrosis: Relevance of the new prognostic classification Francisco Cervantes, MD
2:00 pm Markers other than JAK2 and their significance Heike L. Pahl, PhD
2:30 pm Migration of hematopoetic stem cells and niche abnormalities Speaker invited
3:00 pm Novel therapies and assessing response in PMF Ruben A. Mesa, MD
3:30 pm Break
4:00 pm Update on JAK2 inhibitors Ayalew Tefferi, MD
4:30 pm Clinical significance of endothelial lineage in progression and thrombosis Giovanni Barosi, MD
5:00pm Panel Discussion: Do we know enough to recommend transplantation for PM? Chair: Francisco Cervantes, MD
Confirmed Participant: Damiano Rondelli, MD
Friday November 6, 2009
Session III: Polycythemia Vera and Essential Thrombocythemia Chairs: Nick C.P. Cross, MA, PhD, FRCPath and Richard T. Silver, MD, FACP
8:30 am Genetics of myeloproliferative disorders with emphasis on ET Radek Skoda, MD
9:30 am Gemline and somatic mutations in PV: Clinical significance Josef T. Prchal, MD
10:30 am New genetic abnormalities in MPDs Speaker invited
11:00 am Pegylated Interferon in PV Jean-Jacques Kiladjian, MD, PhD
11:30 am Genotype and phenotype in chronic myeloproliferative disorders Jerry L. Spivak, MD, FACP
12:00 pm Cerebral circulation in PV Richard T. Silver, MD, FACP and Christopher B. Schaffer, PhD
12:30 pm Lunch
Session IV: Polycythemia Vera and Essential Thrombocythemia Chair: Jerry L. Spivak, MD, FACP
1:30 pm Inherited and acquired genetic abnormalities in myeloproliferative disorders Nick C.P. Cross, MA, PhD, FRCPath
2:00 pm Molecular drug targets in myeloproliferative disorders Speaker invited
2:30 pm Reticulin risk factors: Is reticulin and other abnormalities increased by anagrelide? Anthony R. Green, PhD, FRCP, FRCPath
3:30 pm Risk factors for thrombosis in MPDs Tiziano Barbui, MD
4:00 pm Update on clinical studies with anagrelide Heinz Gisslinger, MD
4:30 pm Selected abstract and poster review Chair: Jerry L. Spivak, MD, FACP Confirmed Panel Member: Ruben A. Mesa, MD
5:15 pm Adjourn
Saturday November 7, 2009
Session V: Chronic Myeloid Leukemia (CML) Chairs: John Goldman, MD and Rudiger Hehlmann, MD, PhD
8:30 am Update on biology and pathogenesis John Goldman, MD
9:00 am Monitoring response to therapy / mechanisms of resistance Jerry Radich, MD
9:30 am “Conventional” therapy of CML, including management of pregnancy in CML Hagop M. Kantarjian, MD
10:00 am Break
10:30 am Second and third generation tyrosine kinase inhibitors Jorge Cortes, MD
11:00 am Treatment of accelerated and blast phase disease update Rudiger Hehlmann, MD, PhD
11:30 am Phase III studies: International Speaker invited
12:00 pm Role of transplantation in 2009 Speaker invited
12:30 pm Discussion
1:00 pm Adjourn

Kontakt: meetings@imedex.com

Web: http://www.imedex....ements/a060-01.asp

  • Sdílejte na:
    • Facebook
    • Twitter
    • Del.icio.us
    • Digg
    • Google
    • Reddit
    • StumbleUpon
    • Live